FDA issued a national import warning on Flammulina velutipes produced in South Korea
By: Date: 2022-07-21 Categories: foodwarning Tags: ,
   Food partner online news  2022年7月20日,美国食品药品监督管理局(FDA)宣布,其进口部门可以不经检测扣留从韩国进口的金针菇。

The US FDA issued this nationwide import alert IA #25-21″untested detention of Flammulina velutipes from Korea due to Listeria monocytogenes” to protect public health and help prevent the import of Flammulina velutipes that may be related to human infection. FDA issued import warnings to help prevent potential illegal products from being sold in the United States.
In fiscal year 2021, FDA tests showed that 43%of Flammulina velutipes imported from South Korea were contaminated by L. monocytogenes. Listeria monocytogenes is a human pathogen, which can be found in humid environment, soil, water, rotten vegetation and animals, and can survive and even grow under cold storage and other food preservation measures.
Sampling was conducted after FDA’s investigation of multi state outbreaks from 2016 to 2020. This epidemic has linked many cases of human infection with Listeria monocytogenes to Flammulina velutipes from South Korea. The outbreak resulted in 36 cases reported in 17 states in the United States, 12 in Canada and 6 in Australia. Among the 36 cases in the United States, 31 were hospitalized and 4 died.
From March 2020 to may 2022, the state public health authorities sampled Flammulina velutipes from retail outlets in the United States. Listeria monocytogenes was detected in samples from many states, leading to 21 recalls of Flammulina velutipes in the United States. The nine recalls were related to Flammulina velutipes grown in South Korea and were confirmed by labeling, tracing or whole genome sequencing (WGS).
After the outbreak of the epidemic in 2020, FDA began to implement the prevention strategy of imported special mushrooms, focusing on Flammulina velutipes, in order to protect public health and prevent the outbreak of Listeria monocytogenes in special imported mushrooms in the future. The prevention strategy of FDA is a positive and prudent approach taken by the agency to limit or prevent the recurrence of the root cause of disease outbreaks or adverse events.